| Caitlin Oliver Mcbryde, PT, DPT | |
|
831 1st St N Ste B, Alabaster, AL 35007-8944 | |
| (205) 358-9138 | |
| (205) 358-9139 |
| Full Name | Caitlin Oliver Mcbryde |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 11 Years |
| Location | 831 1st St N Ste B, Alabaster, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740821305 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PTH6926 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Benchmark Physical Therapy Of Alabama, Llc | 5698930444 | 74 |
News Archive
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.
Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful.
Scientists often study mice as a model for human biology and disease, because their basic biological processes are assumed to be essentially the same as those of humans.
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
› Verified 2 days ago
| Provider Name | Agilitas Usa Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1962417444 PECOS PAC ID: 3375454648 Enrollment ID: O20120523000672 |
News Archive
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.
Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful.
Scientists often study mice as a model for human biology and disease, because their basic biological processes are assumed to be essentially the same as those of humans.
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
› Verified 2 days ago
| Provider Name | Benchmark Physical Therapy Of Alabama, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1659642916 PECOS PAC ID: 5698930444 Enrollment ID: O20120629000400 |
News Archive
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.
Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful.
Scientists often study mice as a model for human biology and disease, because their basic biological processes are assumed to be essentially the same as those of humans.
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
› Verified 2 days ago
| Provider Name | Drayer Physical Therapy-alabama, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1023440583 PECOS PAC ID: 5395970560 Enrollment ID: O20150417000513 |
News Archive
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.
Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful.
Scientists often study mice as a model for human biology and disease, because their basic biological processes are assumed to be essentially the same as those of humans.
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Oliver Mcbryde, PT, DPT 8205 Presidents Dr, Hummelstown, PA 17036-8621 Ph: (717) 839-2159 | Caitlin Oliver Mcbryde, PT, DPT 831 1st St N Ste B, Alabaster, AL 35007-8944 Ph: (205) 358-9138 |
News Archive
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.
Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful.
Scientists often study mice as a model for human biology and disease, because their basic biological processes are assumed to be essentially the same as those of humans.
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
› Verified 2 days ago
Lisa Anne Vogel, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 750 Colonial Promenade Pkwy, Suite 4400, Alabaster, AL 35007 Phone: 205-358-1040 Fax: 205-358-1041 | |
Patrick Ogg, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Gilbert Dr, Alabaster, AL 35007 Phone: 205-259-3991 Fax: 205-621-2212 | |
Madeline Grace Lee, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 831 1st St N Ste B, Alabaster, AL 35007 Phone: 205-358-9138 Fax: 205-803-6642 | |
Shelby Grace Troyer, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 831 1st St N, Suite B, Alabaster, AL 35007 Phone: 205-358-9138 Fax: 205-358-9139 | |
Paige Marie Trammell, DPT, OCS, MTC Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 831 1st St N Ste B, Alabaster, AL 35007 Phone: 205-358-9138 Fax: 205-358-9139 | |
Morgan Gibson, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 750 Colonial Promenade Pkwy Ste 4400, Alabaster, AL 35007 Phone: 205-358-1040 Fax: 205-358-1041 | |
Encore Rehabilitation, Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 831 1st St N Ste B, Alabaster, AL 35007 Phone: 205-605-9005 Fax: 205-624-8092 |